Podcasts about bhutani

In a live interview, GoDaddy CEO Aman Bhutani discussed the continued relevance of websites in 2024 amidst the rise of generative AI and evolving digital landscapes. Bhutani highlighted GoDaddy's shift from being just a domain registrar to supporting micro-businesses with tools like the AI-powered platform Airo. He stressed the value websites offer small businesses for … Continue reading Websites in 2024: GoDaddy's Vision with Aman Bhutani #1782 → The post Websites in 2024: GoDaddy's Vision with Aman Bhutani #1782 appeared first on Geek News Central.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Tina Bhutani, MD, CEO and clinical dermatologist at Synergy Dermatology in San Francisco, to explore the evolving role of topical corticosteroids in psoriasis care and their interplay with newer nonsteroidal agents. With the wide array of treatments available today, they highlight the enduring importance of topicals in dermatology practice, even as systemic therapies become increasingly effective. They begin by highlighting the role of topical corticosteroids as a cornerstone of psoriasis management. Dr Bhutani explains that she often uses high-potency options like clobetasol for thick plaques and milder steroids like hydrocortisone for sensitive areas. She shares a practical approach: using steroids for acute flares and transitioning to nonsteroidals, such as tapinarof or roflumilast, for maintenance. This approach emphasizes the versatility of topical treatments, allowing dermatologists to tailor treatments, enhance efficacy, and simplify regimens to improve adherence. They then discuss the unique mechanisms of newer nonsteroidals, particularly tapinarof as an aryl hydrocarbon receptor agonist. This mechanism reduces inflammation through key psoriasis pathways and may even affect memory T cells, contributing to tapinarof's potential remittive effect. For challenging areas, Dr Bhutani offers pearls such as occlusion to boost penetration and creative strategies to address palmoplantar psoriasis. She also introduces an effective maintenance strategy, advising patients to scale back topicals to twice a week during remission to reduce side effects while sustaining symptom control. Tune in to the full episode for actionable insights for dermatologists navigating the balance between traditional and innovative topical therapies in managing psoriasis.

In a live interview, GoDaddy CEO Aman Bhutani discussed the continued relevance of websites in 2024 amidst the rise of generative AI and evolving digital landscapes. Bhutani highlighted GoDaddy's shift from being just a domain registrar to supporting micro-businesses with tools like the AI-powered platform Airo. He stressed the value websites offer small businesses for … Continue reading Websites in 2024: GoDaddy's Vision with Aman Bhutani #1782 → The post Websites in 2024: GoDaddy's Vision with Aman Bhutani #1782 appeared first on Geek News Central.

I spoke with GoDaddy CEO Aman Bhutani live on stage last week at an event hosted by Alix Partners in Palo Alto. GoDaddy is one of those companies that feels tied to an earlier era, but Aman's been CEO since 2019, and he's been building out what he calls adjacencies. The business of the web has really changed in the past few years: the walled-garden, social network era really took over in the past decade, and now huge changes to Google Search and the addition of generative AI have really put a massive strain on the very foundations of the open web. So I started out by asking Aman the question I've asked so many other guests on Decoder in the past year: What is the point of a website in 2024? Links:  If GoDaddy can turn the corner on sexism, who can't? | New York Times (2017) Google Zero is here – now what? | Decoder Five for the Future – GoDaddy | WordPress.org 2024 is shaping up to be the smallest Black Friday ever | GoDaddy GoDaddy's mission to get entrepreneurs up and running fast | Forbes GoDaddy launches a suite of AI tools for small businesses | Fast Company Why make a website? Squarespace CEO Anthony Casalena has ideas | Decoder Wix CEO Avishai Abrahami on why the web isn't dying after all | Decoder How WordPress and Tumblr are keeping the internet weird | Decoder Intuit CEO Sasan Goodarzi | Decoder Transcript: https://www.theverge.com/e/24069405 Credits: Decoder is a production of The Verge and part of the Vox Media Podcast Network. Our producers are Kate Cox and Nick Statt. This episode was edited by Travis Larchuck and Callie Wright. Our supervising producer is Liam James. The Decoder music is by Breakmaster Cylinder. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Our guest for today's podcast is Vishal Bhutani, Chief Investment Officer of AMS Children's Fund (AMS), a new fund launching in early 2025.  Together with David Gaynes, Vishal is forming AMS to capitalize on the growing interest by institutional investors in the Indian equity markets.  Vishal believes that the middle market opportunity in Indian equities is one of the best investment opportunities available today.  Leveraging his experience as an event driven portfolio manager, AMS believes it will be able to achieve superior risk adjusted returns.   Vishal has spent the bulk of his 20 year investment career as an Event Driven investor, investing across the capital structure.  Joining me on the podcast is Clark Cheng, CEO and CIO of Merrimac Corp, a large single family office with investments in hedge funds, private equity, venture capital and real estate AND David Gaynes, co-founder of AMS Children's Fund.   So why should investors care about the Indian equity markets now?  Vishal provides many insights and answers why in this podcast.   Without further ado, here is our conversation with Vishal Bhutani.

Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics.Gurdane is an expert in environmental health, with a background in Epidemiology and Environmental Health Sciences. He provided insights into the pervasive nature of environmental toxins and their implications for public health. This episode also has a guest appearance from Bruce Blumberg, a Professor of Developmental and Cell Biology at UC Davis.In this episode, we discuss:The widespread presence of environmental toxins and their link to diseases like Parkinson's and autismThe field of exposomics and lifetime environmental exposuresObesogens (chemicals whose exposure makes you fat)Startups building solutions for better diagnostics, green chemistry, and water treatmentPractical lifestyle changes to reduce exposure to harmful chemicals and improve healthCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank and Temperance by Eltham House

Lato, lato, lato czeka, Razem z latem czeka WYZWANIE dotyczące troski o Twój własny dobrostan!To ja już Wam zdradzam koncepcję, na to lato, którą mam Wam do zaoferowania. Otóż Benefit Systems w ramach swojego produktu MultiLife zlecił infuture institute przygotowanie raportu na temat całościowego dobrostanu Polek i Polaków. I stworzyli oni także na te cele narzędzie zwane Wellbeing Score, z którego darmowo możecie skorzystać także i Wy, wchodząc na www.multilife.com.pl. Uzupełniacie takie badanie, polecam zarezerwować sobie na to chwilę względnego spokoju i skupienia, a następnie proszę ja Was uzupełniacie i otrzymujecie na maila wynik, w którym Wasz wynik osobisty jest porównywany do średniej w populacji oraz stosowne rekomendacje do tego właśnie jak można się wspierać na danym wymiarze.A wymiarów jest sześć, zatem ten podcast także będzie się składał z sześciu zagadnień które potraktujemy jako wyzwanie, czyli z angielskiego właśnie CZELENDŻ, czyli sobie omawiamy jeden wymiar a kolejne dwa tygodnie poświęcamy na próbę zaopiekowania tego właśnie wymiaru.I kim ja bym była gdybym nie zaczęła od zdrowia psychicznego?Zapraszam do wysłuchania tego odcinka!Podejmujesz wyzwanie? .......................................................Fot. moje @opowiedziane_swiatlemMontaż: Eugeniusz KarlovLiteratura: Budd, M., Iqbal, A., Harding, C., Rees, E., & Bhutani, G. (2021). Mental health promotion and prevention in primary care:What should we be doing vs. what are we actually doing? Mental Health & Prevention, 21, 200195. https://doi.org/10.1016/j.mhp.2020.200195Vaillant-Coindard, E., Briet, G., Lespiau, F. et al. Effects of three prophylactic interventions on French middle-schoolers' mental health: protocol for a randomized controlled trial. BMC Psychol 12, 204 (2024). https://doi.org/10.1186/s40359-024-01723-8

Wollongong resident Hemanta Acharya migrated to Australia in 2008 as a Bhutani refugee. An anaesthetic nurse by profession, she is involved in promoting Nepali culture and has also represented Australia internationally through sports. In occasion of Refugee Week 2024, Acharya spoke to SBS Nepali about her journey from Nepal's refugee camps to becoming a Les Murray Award nominee. - वलङगङ निवासी हेमन्ता आचार्य सन् २००८ मा भुटानी शरणार्थीको रूपमा नेपालबाट अस्ट्रेलिया आएकी थिइन्। अहिले एक 'एनेस्थेटिक' नर्स रहेकी उनले नेपाली भाषा संस्कृतिलाई समुदायमा प्रवर्धन गर्नुका साथै फुटबल मार्फत विश्वस्तरमा अस्ट्रेलियाको प्रतिनिधित्व पनि गरेकी छिन्। हालै सन् २०२४ को लेज मरी पुरस्कारको उम्मेदवार बनेकी आचार्यले १६ देखि २२ जुनसम्म अस्ट्रेलियामा मनाइँदै गरेको शरणार्थी सप्ताहको अवसरमा एसबीएस नेपालीसँग गरेको कुराकानी सुन्नुहोस्।

Summary Dr. Tina Bhutani shares her journey to becoming a dermatologist and the challenges she faced along the way. She emphasizes the importance of being proactive in interviews and marketing oneself effectively. Dr. Bhutani also discusses the rewards and challenges of working in an academic setting, including the bureaucracy and administrative burdens. She highlights the significance of clinical trials and her interest in studying lifestyle modifications and their impact on skin disease. However, she acknowledges the difficulty of getting funding for these types of studies. In this conversation, she discusses her busy life as a dermatologist and the importance of patient-centered research and accessible clinical trials. Dr. Bhutani and Dr. Fara also talk about Dr. Bhutani's book that she co-authored on the use of biologics in psoriasis treatment. The conversation covers various chapters of the book, including laboratory monitoring, TNF-alpha inhibitors, IL-17 class of biologics, combination therapies, biologic agents for pediatric psoriasis, special site psoriasis, comparing biologic agents, long-term registry data, biologic agents in special populations, and adherence to biologic therapy. Dr. Fara and Dr. Bhutani emphasize the importance of individualizing treatment and having open conversations with patients about their preferences and needs.   Takeaways Be proactive in interviews and market yourself effectively Working in an academic setting has rewards and challenges Clinical trials are important for providing access to treatments Studying lifestyle modifications and their impact on skin disease is valuable Obtaining funding for non-traditional studies can be challenging Patient-centered research and accessible clinical trials are important for improving dermatology treatments Dr. Bhutani's book on the use of biologics in psoriasis treatment provides practical guidance and evidence-based recommendations TNF-alpha inhibitors are still valuable in psoriatic arthritis treatment IL-17 class of biologics work quickly and are effective for tough-to-treat areas Combination therapies can be beneficial for patients who have already tried monotherapy Treating special site psoriasis is important for improving quality of life and preventing comorbidities Comparing biologic agents is challenging due to individual patient factors and access issues Long-term registry data provides reassurance about the safety and efficacy of biologic agents Special populations, such as pregnant women and the elderly, require careful consideration in biologic therapy Adherence to biologic therapy is crucial, and treatment should be tailored to individual patient preferences and needs Chapters 00:00 Introduction and Background 08:39 Navigating the Challenges of an Academic Setting 29:27 The Value of TNF-alpha Inhibitors in Psoriatic Arthritis 36:04 Comparing Biologic Agents: Challenges and Considerations

The sixth New and Emerging Communities Festival was held in Melbourne on Sunday, 14 April. Nepali, Bhutani, Vietnamese, Afghani and many more communities took part in the event. Organisers, participants and attendees spoke to SBS Nepali about the significance of cultural diversity in Australia. - विभिन्न नयाँ र उदयमान समुदायहरूलाई समेटेर मेलबर्नको ग्लेन्रोइमा 'न्यु एन्ड इमर्जिङ कम्युनिटी फेस्टिभल' सम्पन्न भएको छ। हेल्प हिमालयन युथ फाउन्डेसन र इटिकी स्पोर्टिङ क्लबको संयुक्त आयोजनामा भएको कार्यक्रममा नेपाली, भुटानी, अफगानी, भियतनामी लगायत विभिन्न समुदायका सदस्यहरूको सहभागिता थियो। अस्ट्रेलियाको सांस्कृतिक विविधताको महत्त्वबारे आयोजक र सहभागीहरूसँग गरिएको कुराकानी सहितको रिपोर्ट सुन्नुहोस्।

Summary In this episode, Dr. Farah Kamangar and Dr. Tina Bhutani discuss the efficacy and safety of Tapinarof, a non-steroidal topical therapy for psoriasis and atopic dermatitis. They highlight the impressive results of clinical trials, with 35-40% of psoriasis patients achieving clear or almost clear skin after 12 weeks of treatment. They also discuss the potential benefits of Tupinarof for atopic dermatitis patients. The side effects of folliculitis and headaches are mentioned, but overall, patients tolerate the medication well. The episode concludes with a discussion on the future of Tapinarof, including potential pediatric indications. This episode is sponsored by an educational grant from the company Dermavant.   Takeaways Tapinarof is a non-steroidal topical therapy that has shown impressive efficacy in treating psoriasis, with 35-40% of patients achieving clear or almost clear skin after 12 weeks of treatment. The medication is also being studied for its effectiveness in treating atopic dermatitis, with early data showing promising results. Common side effects of Tapinarof include folliculitis and headaches, but overall, patients tolerate the medication well. The future of Tapinarof may include pediatric indications, which would be beneficial for parents looking for non-steroidal treatment options for their children. Gentle skincare techniques and moisturization may also play a role in managing psoriasis and improving skin barrier function.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Shauraya Bhutani brings to the table an exceptional combination of being both young and a veteran of the PE space, and he is the co-founder of the boutique investment bank - Capital Connect Advisors. He spills the beans on how to get your startup funded across different levels, and how to be more strategic about engaging with an investment bank to raise funds.For more such interesting founder journeys, subscribe to our newsletter www.founderthesis.comRead more about Capital Connect Advisors:-1.Investment banker Shauraya Bhutani makes it to Forbes Asia's 30 Under 302.India is emerging as a climate tech hub

Gurdane Bhutani and Zeshan Muhammedi are co-founders and GPs at MBX, a VC firm investing in early-stage bio/healthtech companies tackling major public health threats. Prior to that they co-founded healthcare and life-science venture capital firm FundRx, where they championed the firm's build-out of its community-driven investment infrastructure, modeled on the scientific peer-review process. Takeaways: - Pharma companies have realized that it makes sense to develop drugs that will have a population-level health benefit rather than developing drugs for small numbers of people that cost exorbitant amounts. - Noise pollution is actually a big public health issue that is linked to various diseases. Companies are working on making society less noisy using things like concrete that is quieter when cars drive over it. - Gurdane and Zeshan have learned from working together for a long time how to engage in productive disagreement well by acknowledging what their respective strengths and weaknesses are and weighing the strength of one person's enthusiasm against the strength of the other person's skepticism. - Genomics has been a huge story in medicine in the last several decades but hasn't lived up to its promise because we've been missing an understanding of how environmental triggers drive diseases that our genes prime us for. - In the future, given changes at the FDA and EPA, drugs and chemical products will be tested on “organoids on a chip” or high-throughput systems that can give us higher fidelity data than actual tests on living animals. - Studies are often powered to look for benefits of a drug rather than find rare long tail side effects. It often takes years and years for the downsides of a treatment to become apparent.Thanks for listening — if you like what you hear, please review us on your favorite podcast platform.Check us out on the web at www.villageglobal.vc or get in touch with us on Twitter @villageglobal. Want to get updates from us? Subscribe to get a peek inside the Village. We'll send you reading recommendations, exclusive event invites, and commentary on the latest happenings in Silicon Valley. www.villageglobal.vc/signup

More than 4,700 Bhutani refugees have been calling Australia their home, according to the latest census. Nirmala Rai is one of them. When Rai arrived in Tasmania in 2017, learning English and finding a job were some of her many challenges. Overcoming the obstacles, she bought her first home within her first three years in the country. Rai spoke to SBS Nepali on her journey from Bhutan to Nepal and finally calling Australia home. - सन् २०२१ मा सम्पन्न अस्ट्रेलियाको पछिल्लो जनगणना अनुसार देशभर ४,७०० भन्दा बढी भुटानी शरणार्थीहरूले अस्ट्रेलियालाई आफ्नो घर मान्दै आएका छन्। तिनै मध्येकी एक, टास्मेनियाकी निर्मला राई भने सन् २०१७ मा अस्ट्रेलियामा बस्न आउँदा आफूलाई भाषा लगायत थुप्रै कुराको अड्चन थियो भन्छिन्। तर, अनेकौँ चुनौतीहरू पार गर्दै राईले अङ्ग्रेजी भाषा मात्र सिकिनन्, जागिर पाउन सक्ने गरी पठनपाठन पनि गरिन् र अस्ट्रेलिया बसाइँ सरेको तीन वर्ष भित्रै आफ्नै नाममा घर किन्न पनि उनी सफल भएकी छिन्। आफ्नो यो सफलताको पछाडिको सङ्घर्षका कथाहरू बारे उनले एसबीएस नेपालीसँग गरेको कुराकानी सुन्नुहोस्।

Obeth Rai from Tasmania shared his journey from being a refugee in Nepal to becoming an Australian citizen. Despite the bittersweet feeling of not being able to establish an identity in his ancestral land, Rai told SBS Nepali he feels proud to call Australia home. - जुन १८ देखि २४ लाई शरणार्थी सप्ताहका रूपमा मनाइँदै गर्दा टास्मेनिया निवासी ओबेथ राईले शरणार्थीका रूपमा नेपालमा रहँदा देखि अस्ट्रेलियाको नागरिक हुँदासम्मको अनुभव सुनाएका छन्। केही महिनाको शिशु हुँदा भुटानी शरणार्थीका रूपमा नेपाल लगिएका राईले आफ्नो बाल्यकाल र किशोरावस्था नेपालमा बिताएका हुन्। सन् २०१३ मा आफ्नो परिवारसँग अस्ट्रेलिया आएका उनलाई पुर्खाको देश भनेर चिनाइएको नेपालमा आफ्नो अस्तित्व नपाउँदा दुख लागे तापनि अहिले अस्ट्रेलियाको नागरिक हुँ भन्दा गर्व लाग्ने बताए। ओबेथ राईले एसबीएस नेपालीसँग गरेको कुराकानी सुन्नुहोस्।

This year's Refugee Week is being celebrated with the theme "Finding Freedom". Narayan Khanal, who moved to Australia as a Bhutani refugee when he was 12, says freedom can mean different things to different people. He spoke to SBS Nepali about finding his freedom. - वार्षिक रूपमा मनाइने शरणार्थी सप्ताहको सन् २०२३ को नारा "फाइन्डिङ फ्रीडम" अर्थात् "स्वतन्त्रता प्राप्ति" रहेको छ। नेपालको भुटानी शरणार्थी शिविरमा जन्मिएर १२ वर्षको उमेरमा अस्ट्रेलिया आइपुगेका नारायण खनाल भन्छन् स्वतन्त्रताको अर्थ सबैको लागि फरक-फरक हुन सक्छ। शरणार्थी सप्ताहको महत्त्व के हो? खनालसँगको कुराकानी सुन्नुहोस्।

Subscribe to BigTentUSAEpisode RecapLearn More about Civic InfluencersRead WAPO OpEd on The Effort to Silence Young Voter This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit bigtentnews.substack.com

“The unifying theme across our portfolio is that whatever a company we invest in is building can make a population-level health impact. For us, that means that what they're doing is going to lead to innovation that is ultimately accessible to huge portions of the global population,” says Gurdane Bhutani, co-founder and managing partner of MBX Capital, a venture capital partnership dedicated to investing in early-stage companies focused on big public health problems. As he explains to host Shiv Gaglani, that ambitious mission is focused on three main themes: accumulated environmental exposure (exposome), biosecurity and biodefense, and healthcare infrastructure. “The majority of disease pathogenesis today is environmental in nature, not genetic. So we're looking at companies that are developing exposomic sequencing technologies that help us better understand these environmental exposures.” One such company is using human-relevant tissue models to test for environmental contaminants. Others include a nurse scheduling platform and a firm that's localizing radiology systems for underdeveloped areas. Bhutani has a track record of investing in interesting and impactful companies in healthcare (in fact, he was an early backer of Osmosis!) so you won't want to miss his insightful perspective on promising ideas for improving health and healthcare systems.Mentioned in this episode: https://www.mbxcapital.com/

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.12.536625v1?rss=1 Authors: Huckleberry, K. A., Calitri, R., Li, A. J., Mejdell, M., Singh, A., Bhutani, V., Laine, M. A., Nastase, A. S., Morena, M., Hill, M., Shansky, R. M. Abstract: Increasing evidence suggests that the neurobiological processes that govern learning and memory can be different in males and females, and here we asked specifically whether the endocannabinoid (eCB) system could modulate Pavlovian fear conditioning in a sex-dependent manner. Systemic (i.p.) injection of CB1R antagonist AM251 in adult male and female Sprague Dawley rats prior to auditory cued fear conditioning produced a female-specific increase in freezing that persisted across extinction and extinction retrieval tests but was prevented by co-administration of TRPV1R antagonist Capsazepine. Notably, AM251 also produced robust freezing in a novel context prior to auditory cue presentation the day following drug administration, but not the day of, suggesting that CB1R blockade elicited contextual fear generalization in females. To identify a potential synaptic mechanism for these sex differences, we next used liquid chromatography/tandem mass spectrometry, Western Blot, and confocal-assisted immunofluorescence techniques to quantify anandamide (AEA), TRPV1R, and perisomatic CB1R expression, respectively, focusing on the ventral hippocampus (vHip). Fear conditioning elicited increased vHip AEA levels in females only, and in both sexes, CB1R expression around vHip efferents targeting the basolateral amygdala (BLA) was twice that at neighboring vHip neurons. Finally, quantification of the vHip-BLA projections themselves revealed that females have over twice the number of neurons in this pathway that males do. Together, our data support a model in which sexual dimorphism in vHip-BLA circuitry promotes a female-specific dependence on CB1Rs for context processing that is sensitive to TRPV1-mediated disruption when CB1Rs are blocked. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In episode 11 of Cutaneous Miscellaneous, our host Nicholas Brownstone, MD speaks with Tina Bhutani, MD, MAS, Associate Professor of Dermatology at The University of California, San Francisco, Department of Dermatology and Co-Director of the Dermatology Clinical Research Unit and Psoriasis Treatment Center. The episode begins with board review prep on psoriasis. Dr. Bhutani provides high yield pearls on the following topics: drug triggers, co-morbidities, and phototherapy. Dr. Brownstone and Dr. Bhutani then spend the rest of the episode discussing clinical trials. Dr. Bhutani provides information on how residents can better understand and interpret clinical trial data in dermatology. She specifically discusses concepts such as drug efficacy, speed of onset, safety profiles, control groups and non-responder imputation.  In the final part of the episode, Dr. Brownstone asks Dr. Bhutani for tips on how residents can set up a dermatology clinical trials unit after residency. Dr. Bhutani discusses the advantages and disadvantages of running clinical trials in practice along with advice for how residents can start a clinical trials unit with little to no experience in residency.

Gurdane Bhutani, Co-Founder & Managing Partner at MBX Capital join our host, Jared S. Taylor to discuss: Bhutani's background Overview of MBX Capital Investing in Arine, Eva Tech, OFFOR Health His 2023 outlook What's next? To learn more about MBX Capital use the links below:- Website - LinkedInThis episode is presented by Sage Growth Partners.Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartnersProduced by Slice of Healthcare.Also, be sure to follow us on our social channels:- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

Our anchors begin today's show with Moor Insights & Strategy CEO Patrick Moorhead discussing Apple warning of a major slowdown in iPhone 14 shipments. Then, CNBC's Steve Kovach covers reports that Meta could be planning large-scale layoffs, and Truist Co-CIO Keith Lerner explains why he downgraded the entire tech sector. Next, Verge Editor-in-Chief Nilay Patel previews upcoming gaming earnings from Take-Two Interactive and Activision, and CNBC's Seema Mody breaks down the top beneficiaries of investments in domestic chip manufacturing. We also take a closer look at global competition in semiconductors with “Chip War” author Chris Miller, and CNBC's Frank Holland analyzes last week's brutal losses for cloud stocks. Later, GoDaddy CEO Aman Bhutani takes a deep dive into the internet services platform's Q3 results.

In today's podcast, Aman Bhutani - the CEO of Godaddy - shares his incredible leadership journey - from a modest upbringing in India to the CEO of one of the top technology firms in the world. Bhutani's leadership style is refreshing. He completely embraces vulnerability and makes a habit of learning from past mistakes. HIs mindset helps him connect authentically with others and create a culture of continuous improvement. Bhutani shares a powerful metaphor - learned as a child - of a bending mango tree to illuminate the importance of respect, learning, and inclusivity. Everyone - from first time managers and team leaders to powerful chief executive officers - can learn from Bhutani's inspiring story and practical lessons. Any comments, questions or thoughts to share with today's podcast guest - Aman Bhutani - join our community at www.imperfectleaders.com.

In today's podcast, Aman Bhutani - the CEO of Godaddy - shares his incredible leadership journey - from a modest upbringing in India to the CEO of one of the top technology firms in the world. Bhutani's leadership style is refreshing. He completely embraces vulnerability and makes a habit of learning from past mistakes. HIs mindset helps him connect authentically with others and create a culture of continuous improvement. Bhutani shares a powerful metaphor - learned as a child - of a bending mango tree to illuminate the importance of respect, learning, and inclusivity. Everyone - from first time managers and team leaders to powerful chief executive officers - can learn from Bhutani's inspiring story and practical lessons. Any comments, questions or thoughts to share with today's podcast guest - Aman Bhutani - join our community at www.imperfectleaders.com.

Bhumi is the Co-Founder and VP of Strategic Alliances of Way.com, where she's responsible for the strategic alignment, corporate sales, and operational leadership of the company's online organization. Bhumi brings with her over seven years of industry experience, during which she has made hundreds of direct alliances with parking operators and companies, further establishing Way.com's presence to include over 100 cities throughout the United States.Prior to Way.com, Bhumi was the Co-Founder and COO of Raksha International - and has held management positions at Genentech and the California Department of Health. Bhumi received her Master of Science degree from the London School of Economics and her Bachelor of Science degree from the University of California, Berkeley.Host James Lott Jr breakdown how this app works and what it doesway.com

Our anchors begin today's show breaking down the Bureau of Labor Statistics' jobs data for July with CNBC's Mike Santoli, and CNBC's Kate Rooney breaks down the latest earnings from fintech company Block. Next, Wall Street Journal Senior Personal Technology Columnist Joanna Stern discusses Amazon buying Roomba maker iRobot for $1.7 billion, and Twilio CEO Jeff Lawson offers his insight on the enterprise software firm's second quarter. Then, our Julia Boorstin reports on Q2 numbers out of several streamers, and Doximity CEO Jeff Tangney joins after the health tech provider slashed its full-year guidance. Later, GoDaddy CEO Aman Bhutani covers the internet services platform's recent results, and our Julia Boorstin returns with the latest in the Elon Musk-Twitter saga.

Narayan Khanal was born in a refugee camp in Nepal. Now he's representing Australia at the Y20 Summit.   - नेपालमा जन्मेका भुटानी शरणार्थी नारायण खनाल, विश्वका प्रमुख २० देशहरूका युवाहरूले भाग लिने शिखर सम्मेलनमा अस्ट्रेलियालाई प्रतिनिधित्व गर्दै छन्। बहुप्रतिभाशाली व्यक्तित्वका धनी खनाल हाल वलङगङ विश्वविद्यालयमा डाक्टरीको पढाई गरिरहेका छन् र उनी भन्छन् कि आफू जस्तै अल्पसङ्ख्यकहरूको आवाज बुलन्द पार्न शिखर सम्मेलनले उनलाई स्थान दिएको छ। 

Retail continues to be a hot topic in the commercial real estate space. Although we are transitioning to a digital age, physical stores are still important for retail brands. Navin Bhutani, Managing Director at Locate AI, chats with Matt about how brands differentiate themselves with a strong in-person experience, and how physical stores provide the opportunity to deliver a powerful brand experience.

Bhumi Bhutani is the co-founder and VP of strategic alliances for WAY.COM, a supper app designed to save auto users money. As most business travelers use their vehicle for work and/or utilize airport parking lots, WAY.COM can provide savings for us. Bhumi swapped out a future in medicine to be an entrepreneur and start up this successful mobile app company.We talked about how they were able to pivot where needed yet stay focused on their long term goals during the worldwide shutdowns. Maintaining a balance of family friends and work is paramount to Bhumi and we had a nice chat about how similar we are when it comes to work-life balances.Make sure to follow Bhumi and WAY.COM on their social media pages to see the latest on how WAY.COM can save you money.ABOUT Bhumi BhutaniBhumi is the Co-Founder and VP of Strategic Alliances of Way.com - a leading all-in-one car services superapp - responsible for partnerships and sales. Bhumi has over eight years of industry experience during which she made hundreds of direct alliances with companies across various industries including parking, hospitality and automotive/mobility. These alliances helped establish Way.com's rich portfolio of services which expands to thousands of locations and hundreds of cities in North America. On Way, partners engage in invaluable revenue opportunities and customers transact across thousands of car service options on our platform. Prior to Way.com, she was the Co-Founder and COO of Raksha International and held management positions at Genentech and the California Department of Health. She received her Master of Science degree from the London School of Economics and Bachelor of Science degree from the University of California, Berkeley.SUBSCRIBEYou can subscribe to The Travel Wins Podcast on Apple Podcasts, SoundCloud, YouTube, iHeart Radio, Stitcher, Google Podcasts, Spreaker, Podnews, Castbox, Pocket Casts, Radio Public, and Amazon.The Travel Wins intro song by Allison Johnson and Steve StevensWebsite Design by Stack Host#bhumibhutani #way #entrepreneur

03-31-2022 Bhumi Bhutani Learn more about the interview and get additional links here: https://www.thedailyblaze.com/app-creates-marketplace-for-affordable-car-services/ Subscribe to the best of our content here: https://priceofbusiness.substack.com/ Subscribe to our YouTube channel here: https://www.youtube.com/channel/UCywgbHv7dpiBG2Qswr_ceEQ

"Thank You, Australia" is a documentary on Nepali-speaking Bhutani refugees who have settled in Australia. We spoke with Netra Dulal, the director and producer on the hardships of community refugee camps to life in Australia. - साउथ अस्ट्रेलियाको टु स्टार स्टुडियोले नेपाली भाषी भुटानी शरणार्थीहरूको कथा बोकेको "थ्याङ्क यु अस्ट्रेलिया" नामक वृत्तचित्र युट्युबमा सार्वजनिक गरेको छ। समुदायको शरणार्थी शिविरका कठिनाइ देखि, अस्ट्रेलियाको जीवनसम्म समेटेको यस वृत्तचित्रका निर्देशक तथा निर्माता नेत्र दुलालसँगको कुराकानी सुन्नुहोस्।

Shauraya is a Co-Founder at Capital Connect Advisors, a boutique investment bank based in Singapore and New Delhi which provides corporate finance, portfolio management, and ecosystem services to leading tech founders and investors in Asia. Shauraya has been working alongside companies since the early days of the technology wave and has built extensive deal experience, network, and industry expertise working with over 50 technology companies across Southeast Asia and India. Shauraya loves working with upcoming founders and investors to help them navigate the investment landscape. Occasionally, he works on thought pieces and industry deep dives with media outlets such as e27, Business Times, YourStory, and TechInAsia. He recently released Southeast Asia's first YC- style fundraising playbook for founders, co-published with e27. Check out Shauraya's great piece on fundraising here https://www.linkedin.com/pulse/z-becoming-fundraising-legend-tsea-tech-founders-playbook-bhutani/ Read more about CapConnect here https://www.capconnect.asia/ and connect with Shauraya on Linkedin here https://www.linkedin.com/in/shaurayab/ If you enjoyed this podcast, would you consider leaving a short review on Apple Podcasts or Spotify? It takes less than 30 seconds, and it really makes a difference in helping to convince new amazing guests to come on the show, and on top of that, I love reading the reviews! Connect with me: Email: hello@andrewsenduk.com Website: https://andrewsenduk.com/ Instagram: https://www.instagram.com/andrew.senduk/ Linkedin: https://www.linkedin.com/in/andrew-senduk-1980/

When Aman Bhutani took over as CEO of GoDaddy, he realized that the company had a great culture of experimentation — but was lacking a proper system for experimentation. That could be the difference between an interesting company and a thriving one! Here's how he fixed it, and why every entrepreneur should be thinking more systematically about their experiments.

He fell in love with every little thing she liked, and he held on to it even when she moved on.Raghav Bhutani recites this ever so relatable and touching poem "Tumhari Pasand" and only wishes good for her ex lover.

Wow nostalgia! When it's the last day of your college, full of emotions and excitement but all you want is that one person to talk to you.

"People with psoriatic disease are sleeping less and not as well" per dermatologist Dr. Tina Bhutani, Co-Director of the Psoriasis and Skin Treatment Center and Director of the Dermatology Clinical Research Unit at UCSF. Hear Dr. Bhutani discuss why, types of sleep disorders, effects and tips to help improve sleep. Psound Bytes is supported by unrestricted educational grants from Amgen, Bristol Myers Squibb, Janssen, Novartis, Pfizer and UCB. 

This is a podcast article summary of "Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease" by Gauri Bhutani on behalf of coauthors.

Ein Beitrag zum Sanskritwort: Sarva Bhutani Hier findest du: Sanskrit Wörterbuch Seminare zum Thema Sanskrit Seminare mit Sukadev Seminarübersicht Yoga Vidya YouTube Live Kanal Online Seminare Video Seminare Yoga Vidya kostenlose App Yoga Vidya Newsletter Yoga Vidya Online Shop Schon ein kleiner Beitrag kann viel bewegen... Spende an Yoga Vidya e.V.!

Dr. Bhutani of San Diego State University studies intermittent fasting, holiday weight gain and more.

Nit Bhutani, gamertag Summoning, is a competitive fighting games player and metal music aficionado originally from Long Island, NY but now resides in Sweden. He has a long history with the arcade scene aswell as the Tri-State area Mortal Kombat community.KPBCast is a podcast dedicated to bringing you into the culture and community that is known as The Fighting Game Community. Join your hosts KPB Rodimus Prime and KPB Rafael as they sit down with the many players, promoters and personalities that make up the scene.Kick-Punch-Block! is an e-sports team from the New York City area that is dedicated to bringing you content from all aspects of the e-sports world. Follow us on our social media outlets to get all updates on upcoming events that we will be involved with.Follow us on:Twitter: @KickPunchBlockTwitter: @KPBCastTwitch: twitch.tv/KPBLiveFacebook: Kick-Punch-Block!Podcast Theme: ArcadeArtist: Lakey Inspired» Spotify: https://goo.gl/aLkwM5» SoundCloud: https://soundcloud.com/lakeyinspired» Instagram: https://www.instagram.com/lakeyinspired/» Patreon: https://www.patreon.com/lakeyinspired

In this episode, Zack catches up with the real estate aficionados of LocateAI, Co-Founder/CEO Joe Lee and Director of Development, Navin Bhutani. We run through trends they’re seeing in the franchise real estate space, strategies to navigate the retail environment during the pandemic, industries they’re seeing growth in during these times and tools they have to help brands prepare themselves for life after COVID-19. To learn more, check out www.locate.ai!

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.21.213116v1?rss=1 Authors: Geary, C. G., Wilk, V. C., Barton, K. L., Jefferson, P. O., Binder, T., Bhutani, V., Baker, C., Fernando-Peiris, A. J., Mousley, A. L., Rozental, S. F. A., Thompson, H. M., Touchon, J. C., Esteban, D. J., Bergstrom, H. C. Abstract: Gut microbiota influence numerous aspects of host biology, including brain structure and function. Growing evidence implicates gut microbiota in aversive conditioning and anxiety-related behaviors, but research has focused almost exclusively on males. To investigate sex-specific effects of gut dysbiosis on aversive learning and memory, adult female and male C57BL/6N mice were orally administered a moderate dose of non-absorbable antimicrobial medications (ATMs; neomycin, bacitracin, pimaricin) or a control over 10 days. Changes in gut microbiome composition were analyzed by 16S rRNA sequencing. Open field behavior, cued aversive learning, context recall, and cued recall were assessed. Following behavioral testing, the morphology of basolateral amygdala (BLA) principal neuron dendrites and spines was characterized. Results revealed that ATMs induced distinct but overlapping patterns of gut dysbiosis across sex, with stronger effects in females. There were also sex-specific effects on behavior and neuroanatomy. Treated males but not females exhibited altered locomotor and anxiety-like behavior in the novel open field test. Treated females but not males showed impairments in aversive memory acquisition and cued recall. Context recall remained intact in both sexes, as did dendritic structure of BLA principal neurons. However, ATMs exerted sex-specific effects on spine density. A second experiment was conducted to isolate gut perturbation to cued recall. Results revealed no effect of ATMs on recall of a previously consolidated fear memory, suggesting that gut dysbiosis preferentially impacts aversive learning. These data shed new light on how gut microbiota interact with sex to influence aversive conditioning, anxiety-like behavior, and BLA dendritic spine architecture. Copy rights belong to original authors. Visit the link for more info

Home to Whole Foods, Publix, Marine Layer, The Thompson Hotel, and so many more, 12 South and The Gulch - two Nashville neighborhoods separated by less than 2 miles - have quickly become the hottest draws in town. Rents in the neighborhoods have doubled or even tripled in under 5 years! What's driving the growth? LocateAI is a leader in retail real estate analytics and created the industry's first AI-powered retail real estate brokerage. Our data science team uses 180,000 variables to build predictive analytics and market strategy maps for our clients, who rely on this objective data to make optimal real estate expansion decisions. LocateAI provides this data at no cost to retailers – learn more at https://www.locate.ai.

Home to Whole Foods, Equinox, The W Hotel, SoulCycle, ABC Cocina and ABC Kitchen, Gramercy Tavern, and so much more, the Union Square to Flatiron District corridor - bridged by Broadway - is one of the most accessible and busiest 7-day trade areas in all of Manhattan. LocateAI is a leader in retail real estate analytics and created the industry's first AI-powered retail real estate brokerage. Our data science team uses 180,000 variables to build predictive analytics and market strategy maps for our clients, who rely on this objective data to make optimal real estate expansion decisions. LocateAI provides this data at no cost to retailers – learn more at https://www.locate.ai.

Home to the pennant winning Washington Nationals, the Capitol Riverfront is one of the fastest growing office/residential/entertainment nodes in all of DC.

There must be a reason that New York City's NoHo -- North of Houston ("how-stin") -- neighborhood landed star retailers Rumble, Soulcycle, Barry's, Dig, La Colombe, Equinox, Bandier, Kith, and so many more. We sat down with Michael Cohen, Director at Newmark Knight Frank in New York, to understand why.

Apple, Sweetgreen, Dig, Cava, Solidcore, SLT, Hotel Sofitel, and the Ritz-Carlton have all called Philadelphia's Center City neighborhood home - what makes the area so desirable? Navin Bhutani, our Director of Development, sits down with Phillip Azarik, Senior VP at Metro Commercial, to learn what makes Center City so appealing to retailers, hoteliers, Philly natives, and tourists alike.

Navin Bhutani, our Director of Development, sits down with Neal Ohm, Managing Director at Newmark Knight Frank, to learn what makes the NoMad ("North of Madison") neighborhood in New York City so interesting for retailers, hoteliers, and more.

Guest Robert Christensen, MD, FAAP Host Paul Wirkus, MD, FAAP. In episode 1 hear about Dr. Bhutani's work with the nomogram, kernicterus, phototherapy and complications of phototherapy. For more information visit vCurb.com.

An up-and-coming fad diet that has rapidly gained interest. What do we know about it and how can we advise patients that have questions? References: Patterson, R. E., Laughlin, G. A., LaCroix, A. Z., Hartman, S. J., Natarajan, L., Senger, C. M., ... & Gallo, L. C. (2015). Intermittent fasting and human metabolic health. Journal of the Academy of Nutrition and Dietetics, 115(8), 1203-1212. Chaix, A., Zarrinpar, A., Miu, P., & Panda, S. (2014). Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. Cell metabolism, 20(6), 991-1005. Froy, O. (2009). Metabolism and circadian rhythms—implications for obesity. Endocrine reviews, 31(1), 1-24. Hatori, M., Vollmers, C., Zarrinpar, A., DiTacchio, L., Bushong, E. A., Gill, S., ... & Ellisman, M. H. (2012). Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell metabolism, 15(6), 848-860. Trepanowski, J. F., Kroeger, C. M., Barnosky, A., Klempel, M. C., Bhutani, S., Hoddy, K. K., ... & Ravussin, E. (2017). Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults: a randomized clinical trial. JAMA internal medicine, 177(7), 930-938. Farshchi, H. R., Taylor, M. A., & Macdonald, I. A. (2005). Deleterious effects of omitting breakfast on insulin sensitivity and fasting lipid profiles in healthy lean women. The American journal of clinical nutrition, 81(2), 388-396. Morgan, K. J., Zabik, M. E., & Stampley, G. L. (1986). The role of breakfast in diet adequacy of the US adult population. Journal of the American College of Nutrition, 5(6), 551-563. Cho, S., Dietrich, M., Brown, C. J., Clark, C. A., & Block, G. (2003). The effect of breakfast type on total daily energy intake and body mass index: results from the Third National Health and Nutrition Examination Survey (NHANES III). Journal of the American College of Nutrition, 22(4), 296-302. Albertson, A. M., Anderson, G. H., Crockett, S. J., & Goebel, M. T. (2003). Ready-to-eat cereal consumption: its relationship with BMI and nutrient intake of children aged 4 to 12 years. Journal of the American dietetic association, 103(12), 1613-1619. Berkey, C. S., Rockett, H. R. H., Gillman, M. W., Field, A. E., & Colditz, G. A. (2003). Longitudinal study of skipping breakfast and weight change in adolescents. International journal of obesity, 27(10), 1258. Ma, Y., Bertone, E. R., Stanek III, E. J., Reed, G. W., Hebert, J. R., Cohen, N. L., ... & Ockene, I. S. (2003). Association between eating patterns and obesity in a free-living US adult population. American journal of epidemiology, 158(1), 85-92. Taylor, M. A., & Garrow, J. S. (2001). Compared with nibbling, neither gorging nor a morning fast affect short-term energy balance in obese patients in a chamber calorimeter. International journal of obesity, 25(4), 519. Nicklas, T. A., Myers, L., Reger, C., Beech, B., & Berenson, G. S. (1998). Impact of breakfast consumption on nutritional adequacy of the diets of young adults in Bogalusa, Louisiana: ethnic and gender contrasts. Journal of the American Dietetic Association, 98(12), 1432-1438.

Liza Green Golan Mackintosh MD, and Solomon Behar, MD discuss the nuances of managing neonatal hyperbilirubinemia with pediatric superstar/doctor/researcher Vinod Bhutani. Yes, that Dr. Bhutani. To hear Part Two of this interview. Subscribe today at https://www.hippoed.com/peds/rap/

This episode talks about a relation between dropouts, virginity and influencers. How the new trend of dropouts & influencers is spreading across India who have no idea of what to really do with there life and time.

Saate teema on Bhutani kuningakoda ja Bhutan, väike suletud tiibetibudistlik riik Himaalaja mägedes, millest teatakse maailmas vähe. Seda riiki valitseb juba üle saja aasta Kesk-Bhutani halduritest välja kasvanud kuningasugu, Wangchuki perekond. 19. sajandi lõpul võimu haaranud perepea nimetati ametlikult Draakonikuningaks 1907.

Saate teema on Bhutani kuningakoda ja Bhutan, väike suletud tiibetibudistlik riik Himaalaja mägedes, millest teatakse maailmas vähe. Seda riiki valitseb juba üle saja aasta Kesk-Bhutani halduritest välja kasvanud kuningasugu, Wangchuki perekond. 19. sajandi lõpul võimu haaranud perepea nimetati ametlikult Draakonikuningaks 1907.

Today on the podcast, Dave Scudamore, MD, joins us to talk about neonatal jaundice. Dr. Scudamore is the Director of Inpatient Medicine for the Network of Care at Children's Colorado, and he is also an assistant professor of pediatrics in hospital medicine at the University of Colorado School of Medicine. In this episode: The major risk factors for severe jaundice that can cause complications with neonates How to assess mom and baby for the risk factors of neonatal jaundice by reviewing patient history and birth data Difference between the risk factors for elevated bilirubin and the risk factors for neurotoxicity The significance of the ratio between albumin and bilirubin Standard protocols for bilirubin workups and monitoring for risk factors How you can provide elevated patient care by using a patient-centered care approach and considering the context of the case The way to utilize the Bhutani curve to assess risk and the AAP guidelines to initiate phototherapy Understanding the importance of follow ups and their role in intervention

Today on the podcast, Dave Scudamore, MD, joins us to talk about neonatal jaundice. Dr. Scudamore is the Director of Inpatient Medicine for the Network of Care at Children's Colorado, and he is also an assistant professor of pediatrics in hospital medicine at the University of Colorado School of Medicine. In this episode: The major risk factors for severe jaundice that can cause complications with neonates How to assess mom and baby for the risk factors of neonatal jaundice by reviewing patient history and birth data Difference between the risk factors for elevated bilirubin and the risk factors for neurotoxicity The significance of the ratio between albumin and bilirubin Standard protocols for bilirubin workups and monitoring for risk factors How you can provide elevated patient care by using a patient-centered care approach and considering the context of the case The way to utilize the Bhutani curve to assess risk and the AAP guidelines to initiate phototherapy Understanding the importance of follow ups and their role in intervention

Most newborns will have some jaundice.  Most jaundice is benign. So, how can we sort through the various presentations and keep our newborns safe? Pathologic Jaundice When a baby is born with jaundice, it’s always bad.  This is pathologic jaundice, and it’s almost always caught before the baby goes home.  Think about ABO-incompatbility, G6PD deficiency, Crigler-Najjar, metabolic disturbances, and infections to name a few.  Newborns are typically screened and managed. Physiologic Jaundice Physiologic jaundice, on the other hand, is usually fine, until it’s not. All babies have some inclination to develop jaundice.  Their livers are immature.  They may get a little dehydrated, especially if mother’s milk is late to come in.  In today’s practice, we are challenged to catch those at risk for developing complications from rising bilirubin levels. Hyperbilirubinemia is the result of at least one of three processes: you make too much, you don’t process it enough, or you don’t get rid of it fast enough. Increased production Bilirubin mostly comes from the recycling of red blood cells. Heme is broken down in in the liver and spleen to biliverdin then bilirubin. Normal, full term babies without jaundice run a little high -- bilirubin production is two to three times higher than in adults, because they are born with a higher hematocrit.  Also, fetal hemoglobin is great at holding on to oxygen, but has a shorter life span, and high turn-over rate, producing more bilirubin. Impaired conjugation Think of bilirubin as your email.  Unconjugated bilirubin is your unread email.  To process it or get rid of it – you have to open it.  Of course, the more unread messages that accumulate, the more unwell you feel. Conjugated bilirubin is your opened and processed email.  So much easier to sort out, deal with, and get rid of. Decreased excretion Both unread email and unconjugated bilirubin continue to float around in your inbox.  Unconjugated bilirubin keeps getting reabsorbed in the intestinal mucosa through enterohepatic circulation. Processed email and conjugated bilirubin are easier to sort out.  Conjugated bilirubin is water soluble, so it goes right into the read folder in your gallbladder, and is excreted off your inbox.  Later on down the line in the intestine, conjugated bilirubin can’t be reabsorbed through the intestinal mucosa.  Like when you open an email and forget about it – it passes on through, out of your system. Newborns are terrible at answering emails.  There is a lot of unread unconjugated bilirubin is floating around.  The liver and spleen are just not able to keep up. Also, newborns have a double-whammy administrative load.  Normally, bacteria in the gut can further break down conjugated bilirubin to urobilin and get excreted in the urine.  The infant’s gut is relatively sterile, so no admin assistance there.  Just to add to the workload a poor little newborn has to do – he is being sabotaged by extra beta-glucuronidase which will take his hard-earned conjugated bilirubin and unconjugate it again, then recycle it, just like email you “mark as unread”. How Does this All Go Down? The recommended followup is 48 hours after discharge from the nursery for a routine bilirubin check, often in clinic, and often via the transcutaneous route. More Specifically: Infant Discharged Should Be Seen by Age Before age 24 h 72 h Between 24 and 48 h 96 h Between 48 and 72 h 120 h The neonate will end up in your ED off hours, if there is concern, if his status deteriorates, or simply by chance.  We need to know how to manage this presentation, because time is of the essence to avoid complications if hyperbilirubinemia is present. Critical Action #1: Assess risk for developing severe hyperbilirubinemia. This will tell you: check now in ED or defer to clinic (default is to check). Risk Factors for Developing Hyperbilirubinemia Total serum bilirubin/Transcutaneous bilirubin in high-risk zone Jaundice in first 24 hours ABO incompatibility with positive direct Coombs, known hemolytic disease, or elevated ETCO Gestational age 35-36 weeks Prior sibling had phototherapy Cephalohematoma or bruising Exclusive breastfeeding, especially with poor feeding or weight loss East Asian Race Critical Action #2 Check bilirubin and match this with how old the child is -- in hours of life -- at the time of bilirubin measurement. This will tell you: home or admission. Use the Bilitool or Bhutani Nomogram (below).   Can I go Home Now? Risk Stratification for Developing Severe Hyperbilirubinemia. Bhutani et al. Pediatrics. 1999. In general, babies at low-risk and low-intermediate risk can go home (see below).  Babies at high-intermediate or high risk are admitted (see below). Critical Action #3: Assess risk for developing subsequent neurotoxicity. This will tell you: a) phototherapy or b) exchange transfusion     Phototherapy Now?     Exchange Transfusion Now? Threshold for Initiating Exchange Transfusion by Risk Stratum. Bhutani et al. Pediatrics. 1999. Home care The neonate who is safe to go home is well appearing, and not dehydrated.  His total bilirubin is in the low to low-intermediate risk for developing severe hyperbilirubinemia, and he is not at high risk for neurotoxicity based on risk factors. Babies need to stay hydrated.  Breast feeding mothers need encouragement and need to offer feeds 8-12 times/day – an exhausting regimen.  The main message is: stick with it.  Make sure to enlist the family's help and support to keep Mom hydrated, eating well, and resting whenever she can.  Supplementing with formula or expressed breast milk is not routinely needed.  Be explicit that the neonate should not receive water or sugar water – it can cause dangerous hyponatremia.  A moment of solid precautionary advice could avert a disaster in the making. The child’s pediatrician will help more with this, and you can remind nursing mothers of the excellent La Leche League – an international group for breastfeeding support.  They have local groups everywhere, including a hotline to call. Nursery Care If the baby is at high intermediate or high risk for hyperbilirubinemia, then he should be admitted for hydration, often IV.  Most babies with hyperbilirubinemia are dehydrated, which just exacerbates the problem. Bililights or biliblankets, provide the baby with the right blue spectrum of light to isomerize bilirubin to the more soluble form.  Traditionally, we have thought them to be more effective or safer than filtered sunlight.  A recent randomized control trial by Slusher et al. in the New England Journal of Medicine compared filtered sunlight versus conventional phototherapy for safety and efficacy in a resource-poor environment.  These were all term babies with clinically significant jaundice in Nigeria.  To standardize the intervention, they used commercial phototherapy canopies that remove most UV rays. None of them became dehydrated or became sunburned.  The filtered sunlight resulted in a 93% successful treatment versus 90% for conventional phototherapy.  My take away: we now have some evidence basis for using filtered sunlight as an adjunct for babies well enough to go home. Critical Care Although rare, the critically ill neonate with hyperbilirubinemia requires immediate intervention. He will be dehydrated – possibly in shock.  He will be irritable. Or, he may just have a dangerously high bilirubin level – at any minute he could develop bilirubin induced neurologic dysfunction, or BIND, especially when bilirubin concentrations reach or surpass 25 mg/dL (428 micromol/L).  The bilirubin is so concentrated that it leeches past the blood brain barrier and causes neuronal apoptosis.  BIND is a spectrum from acute bilirubin encephalopathy to kernicterus, all involving some disorder in vision, hearing, and later gait, speech, and cognition. Acute bilirubin encephalopathy starts subtly.  The neonate may be sleepy but hypotonic or have a high-pitched cry; he maybe irritable or inconsolable, jittery or lethergic. The dehydration and neurologic dysfnction from the hyperbilirubinemia may even cause fever.  Check the bilirubin in any neonate you are working up for sepsis. Acute bilirubin encephalopathy may progress to an abnormal neurologic exam, seizures, apnea, or coma. Kernicterus is the final, permanent result of bilirubin encephalpathy.  The child may have choreoathetoid cerebral palsy with chorea, tremor, ballismus, and dystonia.  He may have sensorineural hearting loss, or cognitive dysfunction. It is for this reason that any child sick enough to be admitted should be considered for exchange transfusion.  Most babies need just a little gentle rehydration and bililights, but to be sure, the admitting team will look at a separate nomogram to gage the child’s risk and decide whether to pull the trigger on exchange transfusion.  For our purposes, a ballpark estimate is that if the total serum bilirubin is 5 mg/dL above the phototherapy threshold, or if they have any red flag signs or symptoms, then exchange transfusion should be started. Exchange transfusion involves taking small aliquots of blood from the baby and replacing them with donor blood.  It’s often a manual procedure, done with careful monitoring.  It can be done with any combination of umbilical arteries or veins with peripheral arteries or veins.  In general, arteries are the output, veins are for transfusion. The baby may need a double-volume exchange, which ends up replacing about 85% of circulating blood, a single-voume exchange, replacing about 60% of blood, or any fraction of that with apartial volume exchange.  It is a very delicate procedure that requires multiple hours and often multiple staff. For our pruposes, just be aware that the jaundiced baby in front of you may need escalation of his care. Summary Find out the hour of life of the baby at the time of bilirubin measurement.  Identify risk factors for developing severe hyperbilirubinemia and/or neurotoxicity The child with low to low-intermediate risk may be a good outpatient candidate provided he is well, not dehydrated, and follow-up is assured. The child with high-intermediate to high-risk for developing severe hyperbilirubinemia should be admitted for hydration, bililights, and/or assessment for exchange transfusion. The unwell child with or without current neurologic findings should have immediate exchange transfusion. References Benitz WE. Hospital Stay for Healthy Term Newborn Infants. Pediatrics. 2015; 135(5):948-53. Bhutani V et al. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2004; 114(1). Bhutani VK, Wong RJ. Bilirubin Neurotoxicity in Preterm Infants: Risk and Prevention. J Clin Neonatol. 2013 Apr-Jun; 2(2): 61–69. Bosschaart N et al. Limitations and Opportunities of Transcutaneous Bilirubin Measurements. Pediatrics. 2012; 129(4). Colletti JE, Kothari S, Jackson DM, Kilgore KP, Barringer K. An emergency medicine approach to neonatal hyperbilirubinemia. Emerg Med Clin North Am. 2007 Nov;25(4):1117-35, vii. Gamaleldin R et al. Risk Factors for Neurotoxicity in Newborns With Severe Neonatal Hyperbilirubinemia. Pediatrics. 2011; 128(4):825-31. Lauer BJ, Spector ND. Hyperbilirubinemia in the Newborn. Pediatrics in Review. 2011; 32(8):341-9. Maisels J et al. Hyperbilirubinemia in the Newborn Infant ≥35 Weeks’ Gestation: An Update With Clarifications. Pediatrics. 2009; 124(4):1193-6. Smitherman H, Stark AR, Bhutani VK. Early recognition of neonatal hyperbilirubinemia and its emergent management.  Semin Fetal Neonatal Med. 2006 Jun;11(3):214-24. Vandborg PK, Hansen BM, Greisen G, Ebbesen F. Dose-response relationship of phototherapy for hyperbilirubinemia. Pediatrics. 2012 Aug;130(2):e352-7. This post and podcast are dedicated to Gita Pensa, MD, for her commitment to #FOAMed and passion for asynchronous learning and education innovation.

bAlamodini Stories 2005-2009 2005-10 prakRRitiM yAnti bhUtAni SS-2005-10-pg11-prakRRitiM-yAnti-bhUtAni-anAmikaH.mp3

Kuld ja sead ei tee õnnelikuks. Kas aga sisemaine kogutoodang on näitaja inimeste õnnetunde määramisel või on see midagi muud nagu arvab Bhutani kuningriik ja on pannud selle kirja oma põhiseadusesse. Reisirada vaatab miks on just need maad õnnelike maade nimekirja tipus ning uurib kas kõik on ikka kuld mis hiilgab. (Thea Karin.)